A family office based in the USA invests in primarily early-stage (seed, Series A, Series B) companies with truly innovative technologies. The firm will generally lead investments and invests globally with no geographic restrictions.
The firm is agnostic across life science sectors, including therapeutics, devices and tools, but will not consider healthcare IT or digital health technologies. The firm focuses on discovery, early stage preclinical and clinical-stage opportunities, though may be open to commercial-stage or adjacent discovery/ development technologies.
The firm is seeking companies with founders who have a clear vision and desire to build a durable business.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Leave a Reply